- Home
- CALC vs FGF Comparison
CALC vs FGF Comparison
Compare CALC & FGF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- FGF
- Stock Information
- Founded
- CALC 2011
- FGF 2012
- Country
- CALC United States
- FGF United States
- Employees
- CALC N/A
- FGF N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- FGF Property-Casualty Insurers
- Sector
- CALC Health Care
- FGF Finance
- Exchange
- CALC Nasdaq
- FGF Nasdaq
- Market Cap
- CALC 22.9M
- FGF 20.9M
- IPO Year
- CALC N/A
- FGF N/A
- Fundamental
- Price
- CALC $2.13
- FGF $17.05
- Analyst Decision
- CALC Strong Buy
- FGF
- Analyst Count
- CALC 2
- FGF 0
- Target Price
- CALC $14.50
- FGF N/A
- AVG Volume (30 Days)
- CALC 38.7K
- FGF 5.9K
- Earning Date
- CALC 08-11-2025
- FGF 08-13-2025
- Dividend Yield
- CALC N/A
- FGF N/A
- EPS Growth
- CALC N/A
- FGF N/A
- EPS
- CALC N/A
- FGF N/A
- Revenue
- CALC N/A
- FGF $13,260,000.00
- Revenue This Year
- CALC N/A
- FGF N/A
- Revenue Next Year
- CALC N/A
- FGF N/A
- P/E Ratio
- CALC N/A
- FGF N/A
- Revenue Growth
- CALC N/A
- FGF N/A
- 52 Week Low
- CALC $1.42
- FGF $14.21
- 52 Week High
- CALC $5.97
- FGF $38.40
- Technical
- Relative Strength Index (RSI)
- CALC 48.14
- FGF 52.55
- Support Level
- CALC $1.59
- FGF $16.30
- Resistance Level
- CALC $1.69
- FGF $17.98
- Average True Range (ATR)
- CALC 0.15
- FGF 0.60
- MACD
- CALC 0.01
- FGF -0.02
- Stochastic Oscillator
- CALC 46.51
- FGF 54.68
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segments includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.